KDR and neoplasm: The kinase insert domain receptor (KDR, a type IV receptor tyrosine kinase), also known as vascular endothelial growth factor receptor 2 (VEGFR-2), is largely recognized as a potent therapeutic molecular target for the development of angiogenesis-related tumor treatment [1].